Comparison of antitumor efficacy between arsacetyl and arsenic trioxide in vitro

• Published in: Ai zheng = Aizheng = Chinese journal of cancer Vol. 21; no. 4; p. 395
• Main Authors: Huang, Feng-ling, Wang, Yuan-liang, Chen, Chun-xiao, Wang, Hui-nan
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2002
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Arsenicals - chemistry; Arsenicals - pharmacology; Carcinoma, Hepatocellular - pathology; DNA Fragmentation - drug effects; Drug Screening Assays, Antitumor; Endothelium, Vascular - drug effects; Flow Cytometry; G1 Phase - drug effects; Humans; Inhibitory Concentration 50; Liver Neoplasms - pathology; Oxides - pharmacology; Resting Phase, Cell Cycle - drug effects; Tumor Cells, Cultured

Recently, it was reported that some organic arsenics was stronger than inorganic arsenics in inducing carcinoma cell apoptosis. This study was designed to compare arsacetyl (ASAC), a kind of organic arsenics, with As2O3 in the effect of inhibiting proliferation and inducing apoptosis in carcinoma cells. MTT (Methythiazolyl tetrazolium) assay and analysis of apoptosis were used to evaluate the effects of arsacetyl and As2O3 on the proliferation of SMMC-7721 and their mechanisms. Their toxicity to vessel endothelium cells (VECs) was also determined by using MTT method. Both As2O3 and arsacetyl significantly inhibited the proliferation of SMMC-7721, the inhibitory effect was dose- and time-dependent and arsacetyl was stronger than As2O3 [e.g. inhibitory ratio: (14.2 +/- 1.5)%, treated with 0.1 mumol/L arsacetyl for 48 h; (27.1 +/- 3.0)%, treated with 0.1 mumol/L arsacetyl for 48 h]. 1 mumol/L As2O3 and 0.1 mumol/L arsacetyl almost had no toxicity to VEC, while they induced SMMC-7721 apoptosis indicated morpholog